PDF) A Mechanistic Proof-of-concept Clinical Trial With JX-594, a Targeted Multi-mechanistic Oncolytic Poxvirus, in Patients With Metastatic Melanoma
Sequential Therapy With JX-594, A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma: Preclinical and Clinical Demonstration of Combination Efficacy - ScienceDirect
Systemic Armed Oncolytic and Immunologic Therapy for Cancer with JX-594, a Targeted Poxvirus Expressing GM-CSF: Molecular Therapy
Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets | Journal of Experimental & Clinical Cancer Research | Full Text
Viruses as nanomedicine for cancer | IJN
Full article: Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. | Semantic Scholar
Genetically engineered virus kills liver cancer and significantly prolongs life
Systemic Armed Oncolytic and Immunologic Therapy for Cancer with JX-594, a Targeted Poxvirus Expressing GM-CSF - ScienceDirect
Sequential Therapy With JX-594, A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma: Preclinical and Clinical Demonstration of Combination Efficacy - ScienceDirect
Viruses as nanomedicine for cancer - Document - Gale Academic OneFile
Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics | Journal for ImmunoTherapy of Cancer | Full Text
Pexa-Vec/Nexavar Combination Fails Phase III Trial in Liver Cancer
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer | Nature Medicine
JX-594 is selectively delivered to, and amplified within, tumours after... | Download Scientific Diagram
Biomedicines | Free Full-Text | Systemic Injection of Oncolytic Vaccinia Virus Suppresses Primary Tumor Growth and Lung Metastasis in Metastatic Renal Cell Carcinoma by Remodeling Tumor Microenvironment | HTML
A Mechanistic Proof-of-concept Clinical Trial With JX-594, a Targeted Multi-mechanistic Oncolytic Poxvirus, in Patients With Metastatic Melanoma: Molecular Therapy
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial - The Lancet Oncology
Pexa-Vec (JX-594) | SILLAJEN
The immune microenvironment and progression of immunotherapy and combination therapeutic strategies for hepatocellular carcinoma
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer | Nature Medicine
The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. - Abstract - Europe PMC
Viruses as nanomedicine for cancer | IJN
Systemic Armed Oncolytic and Immunologic Therapy for Cancer with JX-594, a Targeted Poxvirus Expressing GM-CSF - ScienceDirect
VX2 rabbit tumor model development for use with JX-594. (A) Replicative... | Download Scientific Diagram
Systemic Armed Oncolytic and Immunologic Therapy for Cancer with JX-594, a Targeted Poxvirus Expressing GM-CSF – topic of research paper in Biological sciences. Download scholarly article PDF and read for free on
The oncolytic Newcastle disease virus as an effective immunotherapeutic strategy against glioblastoma in: Neurosurgical Focus Volume 50 Issue 2 (2021) Journals
